New VP2 chemiluminescent assay targets FMDV serotypes O and A

A new paper in Veterinary Sciences describes a recombinant VP2-based competitive chemiluminescent enzyme immunoassay designed to detect antibodies against foot-and-mouth disease virus serotypes O and A rapidly and in parallel. Based on the study abstract provided, the assay uses a 35% percentage inhibition cutoff and showed a reported relative sensitivity of 101.5%, alongside high specificity, suggesting a potentially useful new serology tool for FMD surveillance and vaccine monitoring.

That matters because foot-and-mouth disease is still one of the most consequential livestock diseases globally. WOAH describes FMD as a highly transmissible disease of susceptible cloven-hoofed animals and recognizes seven viral serotypes: A, O, C, Asia 1, SAT 1, SAT 2, and SAT 3. Serotype O is the most widely distributed, and immunity remains serotype-specific, which is why surveillance and post-vaccination monitoring often need to measure antibodies against individual vaccine components rather than treating FMD exposure as a single category. (woah.org)

The broader diagnostic backdrop helps explain the interest in this study. WOAH’s Terrestrial Code says that when multivalent vaccines are used, antibody testing should determine levels for at least each serotype represented in the vaccine. At the same time, existing type-specific antibody ELISAs for O, A, and Asia 1 are already used in surveillance and outbreak settings, while non-structural protein assays fill a different role by helping distinguish infection from vaccination in DIVA-style programs. In other words, labs already have tools, but they often involve separate serotype-specific workflows or more complex reference methods. (woah.org)

The VP2 angle is notable. Published FMD literature has identified VP2 as diagnostically relevant, including conserved antigenic regions and prior VP2-based assays aimed at broader or serotype-linked antibody detection. Other groups have also been pushing chemiluminescent formats for FMD because they can be faster, more automatable, and less dependent on live virus than virus neutralization tests. Recent examples include chemiluminescent assays for serotype A neutralizing antibodies and earlier recombinant or VLP-based ELISAs for serotypes O and A. This new study appears to combine those threads: recombinant antigen, competitive format, and chemiluminescent readout, with a focus on simultaneous O and A antibody detection. (mdpi.com)

I didn’t find a separate institutional press release or clear outside expert commentary tied specifically to this paper. But the surrounding field points to why researchers keep iterating on FMD serology. WOAH and reference-laboratory materials emphasize that surveillance systems need rapid sample collection, transport, and testing capacity, and that serology is central both for demonstrating freedom from disease and for monitoring vaccinated populations. Commercial suppliers also continue to market separate serotype-specific O and A antibody ELISAs, underscoring the practical demand for assays that are easier to run at scale. (woah.org)

Why it matters: For veterinary professionals, especially those working in livestock health, regulatory medicine, diagnostics, or vaccine programs, the key question isn’t whether FMD serology is important, it’s whether a new assay improves workflow enough to change practice. If this cCLEIA can reliably detect antibodies to both O and A with strong agreement to established methods, it could support faster post-vaccination monitoring, herd immunity assessment, and outbreak-era surveillance. That’s especially relevant in regions using multivalent vaccines, where WOAH explicitly recommends serotype-by-serotype antibody assessment. The caveat is that publication-level performance doesn’t automatically translate into regulatory acceptance or routine lab adoption; reproducibility across species, labs, and field conditions will matter. (woah.org)

Another practical consideration is fit for purpose. Structural-protein antibody assays are useful for serotype-specific immunity monitoring, but they don’t replace non-structural protein tests used to support infected-versus-vaccinated interpretation. For veterinary diagnosticians, that means this kind of assay would likely complement, not replace, existing FMD testing stacks. Inference: if validated, its strongest role may be in vaccine matching and post-vaccination seromonitoring rather than standalone outbreak confirmation. That inference is supported by WOAH surveillance guidance and the way current commercial FMD antibody kits are positioned. (woah.org)

What to watch: Watch for the full paper’s detailed validation dataset, independent comparisons with virus neutralization and established ELISAs, any multi-species field validation, and signs that a reference laboratory or commercial diagnostics company picks up the format for broader deployment. (woah.org)